Comparison of the QuantiFERON-TB gold plus and QuantiFERON-TB gold in-tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers

Elitza S. Theel, Heather Hilgart, Margaret Breen-Lyles, Kevin McCoy, Rhiannon Flury, Laura E. Breeher, John Wilson, Irene Gaw Sia, Jennifer A. Whitaker, Jeremy Clain, Timothy Aksamit, Patricio Escalantec

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germantown, MD) interferon gamma release assay (IGRA) received FDA clearance in 2017 and will replace the prior version of the assay, the QFT-Gold In-Tube (QFT-GIT). Here, we compared performances of the QFT-Plus assay and the QFT-GIT version in a diverse patient population, including patients undergoing evaluation for or follow-up of latent tuberculosis infection (LTBI; n= 39) or active TB infection (n= 3), and in health care workers (HCWs; n= 119) at Mayo Clinic (Rochester, MN). Compared to the QFTGIT, the QFT-Plus assay showed 91.2% (31/34) positive, 98.4% (124/126) negative, and 96.6% (156/161) overall qualitative agreement among the 161 enrolled subjects, with a Cohen's kappa value of 0.91 (excellent interrater agreement). Among the 28 patients diagnosed with LTBI at the time of enrollment, the QFT-GIT and QFT-Plus assays agreed in 24 (85.7%) patients; in all four discordant patients, the positivity of the QFT-GIT or QFT-Plus IGRA was associated with low-level interferon gamma (IFN-γ) reactivity, ranging from 0.36 IU/ml to 0.66 IU/ml. Additionally, we document a high degree of correlation between IFN-γ levels in the QFT-GIT TB antigen tube and each of the two QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes (Pearson's correlation coefficients [R]> 0.95). Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections. Our findings suggest that the necessary transition to the QFT-Plus assay will be associated with a minimal difference in assay performance characteristics.

Original languageEnglish (US)
JournalJournal of Clinical Microbiology
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Interferon-gamma Release Tests
Gold
Tuberculosis
Delivery of Health Care
Latent Tuberculosis
Antigens
Infection
Population
Interferon-gamma

Keywords

  • IGRA
  • LTBI
  • QuantiFERON-TB Gold In-Tube
  • QuantiFERON-TB gold plus

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Comparison of the QuantiFERON-TB gold plus and QuantiFERON-TB gold in-tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers. / Theel, Elitza S.; Hilgart, Heather; Breen-Lyles, Margaret; McCoy, Kevin; Flury, Rhiannon; Breeher, Laura E.; Wilson, John; Sia, Irene Gaw; Whitaker, Jennifer A.; Clain, Jeremy; Aksamit, Timothy; Escalantec, Patricio.

In: Journal of Clinical Microbiology, Vol. 56, No. 7, 01.07.2018.

Research output: Contribution to journalArticle

Theel, Elitza S. ; Hilgart, Heather ; Breen-Lyles, Margaret ; McCoy, Kevin ; Flury, Rhiannon ; Breeher, Laura E. ; Wilson, John ; Sia, Irene Gaw ; Whitaker, Jennifer A. ; Clain, Jeremy ; Aksamit, Timothy ; Escalantec, Patricio. / Comparison of the QuantiFERON-TB gold plus and QuantiFERON-TB gold in-tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers. In: Journal of Clinical Microbiology. 2018 ; Vol. 56, No. 7.
@article{2f066be69e07433aa622307fa742d5f3,
title = "Comparison of the QuantiFERON-TB gold plus and QuantiFERON-TB gold in-tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers",
abstract = "The QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germantown, MD) interferon gamma release assay (IGRA) received FDA clearance in 2017 and will replace the prior version of the assay, the QFT-Gold In-Tube (QFT-GIT). Here, we compared performances of the QFT-Plus assay and the QFT-GIT version in a diverse patient population, including patients undergoing evaluation for or follow-up of latent tuberculosis infection (LTBI; n= 39) or active TB infection (n= 3), and in health care workers (HCWs; n= 119) at Mayo Clinic (Rochester, MN). Compared to the QFTGIT, the QFT-Plus assay showed 91.2{\%} (31/34) positive, 98.4{\%} (124/126) negative, and 96.6{\%} (156/161) overall qualitative agreement among the 161 enrolled subjects, with a Cohen's kappa value of 0.91 (excellent interrater agreement). Among the 28 patients diagnosed with LTBI at the time of enrollment, the QFT-GIT and QFT-Plus assays agreed in 24 (85.7{\%}) patients; in all four discordant patients, the positivity of the QFT-GIT or QFT-Plus IGRA was associated with low-level interferon gamma (IFN-γ) reactivity, ranging from 0.36 IU/ml to 0.66 IU/ml. Additionally, we document a high degree of correlation between IFN-γ levels in the QFT-GIT TB antigen tube and each of the two QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes (Pearson's correlation coefficients [R]> 0.95). Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections. Our findings suggest that the necessary transition to the QFT-Plus assay will be associated with a minimal difference in assay performance characteristics.",
keywords = "IGRA, LTBI, QuantiFERON-TB Gold In-Tube, QuantiFERON-TB gold plus",
author = "Theel, {Elitza S.} and Heather Hilgart and Margaret Breen-Lyles and Kevin McCoy and Rhiannon Flury and Breeher, {Laura E.} and John Wilson and Sia, {Irene Gaw} and Whitaker, {Jennifer A.} and Jeremy Clain and Timothy Aksamit and Patricio Escalantec",
year = "2018",
month = "7",
day = "1",
doi = "10.1128/JCM.00614-18",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Comparison of the QuantiFERON-TB gold plus and QuantiFERON-TB gold in-tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers

AU - Theel, Elitza S.

AU - Hilgart, Heather

AU - Breen-Lyles, Margaret

AU - McCoy, Kevin

AU - Flury, Rhiannon

AU - Breeher, Laura E.

AU - Wilson, John

AU - Sia, Irene Gaw

AU - Whitaker, Jennifer A.

AU - Clain, Jeremy

AU - Aksamit, Timothy

AU - Escalantec, Patricio

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germantown, MD) interferon gamma release assay (IGRA) received FDA clearance in 2017 and will replace the prior version of the assay, the QFT-Gold In-Tube (QFT-GIT). Here, we compared performances of the QFT-Plus assay and the QFT-GIT version in a diverse patient population, including patients undergoing evaluation for or follow-up of latent tuberculosis infection (LTBI; n= 39) or active TB infection (n= 3), and in health care workers (HCWs; n= 119) at Mayo Clinic (Rochester, MN). Compared to the QFTGIT, the QFT-Plus assay showed 91.2% (31/34) positive, 98.4% (124/126) negative, and 96.6% (156/161) overall qualitative agreement among the 161 enrolled subjects, with a Cohen's kappa value of 0.91 (excellent interrater agreement). Among the 28 patients diagnosed with LTBI at the time of enrollment, the QFT-GIT and QFT-Plus assays agreed in 24 (85.7%) patients; in all four discordant patients, the positivity of the QFT-GIT or QFT-Plus IGRA was associated with low-level interferon gamma (IFN-γ) reactivity, ranging from 0.36 IU/ml to 0.66 IU/ml. Additionally, we document a high degree of correlation between IFN-γ levels in the QFT-GIT TB antigen tube and each of the two QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes (Pearson's correlation coefficients [R]> 0.95). Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections. Our findings suggest that the necessary transition to the QFT-Plus assay will be associated with a minimal difference in assay performance characteristics.

AB - The QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germantown, MD) interferon gamma release assay (IGRA) received FDA clearance in 2017 and will replace the prior version of the assay, the QFT-Gold In-Tube (QFT-GIT). Here, we compared performances of the QFT-Plus assay and the QFT-GIT version in a diverse patient population, including patients undergoing evaluation for or follow-up of latent tuberculosis infection (LTBI; n= 39) or active TB infection (n= 3), and in health care workers (HCWs; n= 119) at Mayo Clinic (Rochester, MN). Compared to the QFTGIT, the QFT-Plus assay showed 91.2% (31/34) positive, 98.4% (124/126) negative, and 96.6% (156/161) overall qualitative agreement among the 161 enrolled subjects, with a Cohen's kappa value of 0.91 (excellent interrater agreement). Among the 28 patients diagnosed with LTBI at the time of enrollment, the QFT-GIT and QFT-Plus assays agreed in 24 (85.7%) patients; in all four discordant patients, the positivity of the QFT-GIT or QFT-Plus IGRA was associated with low-level interferon gamma (IFN-γ) reactivity, ranging from 0.36 IU/ml to 0.66 IU/ml. Additionally, we document a high degree of correlation between IFN-γ levels in the QFT-GIT TB antigen tube and each of the two QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes (Pearson's correlation coefficients [R]> 0.95). Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections. Our findings suggest that the necessary transition to the QFT-Plus assay will be associated with a minimal difference in assay performance characteristics.

KW - IGRA

KW - LTBI

KW - QuantiFERON-TB Gold In-Tube

KW - QuantiFERON-TB gold plus

UR - http://www.scopus.com/inward/record.url?scp=85049165628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049165628&partnerID=8YFLogxK

U2 - 10.1128/JCM.00614-18

DO - 10.1128/JCM.00614-18

M3 - Article

C2 - 29743310

AN - SCOPUS:85049165628

VL - 56

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 7

ER -